NasdaqGM:ALT - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2028	73	-84	-140	-156	8
12/31/2027	N/A	-154	-114	-130	10
12/31/2026	0	-130	-103	-116	10
12/31/2025	0	-88	-68	-68	N/A
9/30/2025	0	-84	-66	-66	N/A
6/30/2025	0	-88	-82	-82	N/A
3/31/2025	0	-90	-80	-80	N/A
12/31/2024	0	-95	-80	-80	N/A
9/30/2024	0	-104	-78	-78	N/A
6/30/2024	0	-101	-71	-71	N/A
3/31/2024	0	-93	-73	-73	N/A
12/31/2023	0	-88	-76	-76	N/A
9/30/2023	0	-78	-77	-77	N/A
6/30/2023	0	-81	-71	-71	N/A
3/31/2023	0	-85	-69	-68	N/A
12/31/2022	0	-85	-63	-63	N/A
9/30/2022	3	-87	-67	-67	N/A
6/30/2022	3	-97	-70	-70	N/A
3/31/2022	4	-102	-80	-72	N/A
12/31/2021	4	-97	-91	-78	N/A
9/30/2021	3	-84	-82	-70	N/A
6/30/2021	6	-68	-74	-61	N/A
3/31/2021	7	-60	-54	-50	N/A
12/31/2020	8	-49	-35	-34	N/A
9/30/2020	6	-43	-23	-23	N/A
6/30/2020	4	-36	-16	-16	N/A
3/31/2020	5	-22	-12	-12	N/A
12/31/2019	6	-21	-10	-10	N/A
9/30/2019	8	-42	N/A	-13	N/A
6/30/2019	10	-34	N/A	-11	N/A
3/31/2019	11	-40	N/A	-8	N/A
12/31/2018	10	-42	N/A	-9	N/A
9/30/2018	11	-29	N/A	-9	N/A
6/30/2018	13	-58	N/A	-12	N/A
3/31/2018	13	-52	N/A	-20	N/A
12/31/2017	11	-51	N/A	-20	N/A
9/30/2017	9	-43	N/A	-17	N/A
6/30/2017	5	-16	N/A	-15	N/A
3/31/2017	3	-14	N/A	-8	N/A
12/31/2016	3	-11	N/A	-6	N/A
9/30/2016	3	-10	N/A	-7	N/A
12/31/2015	5	-7	N/A	-5	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: ALT önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: ALT önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: ALT önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: ALT şirketinin gelirinin (yıllık 65.8% ) US pazarından (yıllık 10.3% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: ALT şirketinin gelirinin (yıllık 65.8% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: ALT 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/03/30 09:08
Gün Sonu Hisse Fiyatı	2026/03/30 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Altimmune, Inc. 18 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Eliana Merle	Barclays
William Wood	B. Riley Securities, Inc.
Mayank Mamtani	B. Riley Securities, Inc.

Altimmune Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 11% to US$21.29

Consensus revenue estimates decrease by 29%

Consensus revenue estimates increase by 11%

Price target decreased by 21% to US$19.38

Price target decreased by 11% to US$26.25

Price target decreased by 11% to US$26.25

Recent updates

Altimmune: The High Cost Of Going Solo (Rating Downgrade)

Altimmune, Inc. to Report Q4, 2025 Results on Mar 05, 2026

Altimmune, Inc., Annual General Meeting, Apr 16, 2026

Altimmune, Inc. has completed a Follow-on Equity Offering in the amount of $74.99535 million.

Altimmune, Inc. has filed a Follow-on Equity Offering in the amount of $74.99535 million.

Altimmune, Inc. Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

Altimmune, Inc. Announces Positive Topline Results from the Impact Phase 2B Mash Trial

Altimmune, Inc. Announces CEO Changes

Altimmune, Inc. Announces Publication of Impact Phase 2B Trial Data in the Lancet and Concurrent Late-Breaking Oral Presentation At Aasld the Liver Meeting®? 2025

Altimmune, Inc. Presents Ai-Based Analysis of Liver Fibrosis Reduction from Impact Phase 2B Trial of Pemvidutide Inash in Late-Breaking Poster At Aasld the Liver Meeting®? 2025

Altimmune, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Altimmune, Inc. Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Altimmune, Inc. to Report Q3, 2025 Results on Nov 06, 2025

Altimmune, Inc. Announces the Appointment of Christophe Arbet-Engels as Chief Medical Officer, Effective October 1, 2025

Altimmune, Inc. Appoints Linda M. Richardson to the Role of Chief Commercial Officer, Effective September 16, 2025

Altimmune, Inc. Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Altimmune, Inc., Annual General Meeting, Sep 25, 2025

Holzer & Holzer, Llc Files Shareholder Class Action Lawsuit Against Altimmune, Inc

Altimmune Appoints Jerry Durso as Chairman, Effective August 12, 2025

Levi & Korsinsky, LLP Announces Filing of Class Action Against Altimmune, Inc

Altimmune, Inc. to Report Q2, 2025 Results on Aug 12, 2025

Altimmune, Inc. Announces Initiation of Restore Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease

Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 3000E Value Index

Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH

Altimmune, Inc. Announces Initiation of RECLAIM Phase 2 Trial Evaluating Efficacy and Safety of Pemvidutide in Alcohol Use Disorder

Altimmune, Inc. announced that it expects to receive $100 million in funding from Hercules Capital, Inc.

Altimmune, Inc. to Report Q1, 2025 Results on May 13, 2025

Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine

Altimmune, Inc. Announces Retirement of Scott Harris as Chief Medical Officer, Effective February 28, 2026

Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2

Altimmune, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Altimmune, Inc. Announces Board Appointments

Altimmune, Inc. to Report Q4, 2024 Results on Feb 27, 2025

Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH

Is Altimmune (NASDAQ:ALT) In A Good Position To Invest In Growth?

Altimmune Could Find A Partner For Its Phase 3 Exercise

Altimmune 2025: Redefining Obesity And MASH Treatment

Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024

Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health

Altimmune, Inc. Appoints Greg Weaver as Chief Financial Officer

Altimmune, Inc. Announces Successful Completion of End-of-Phase 2 Meeting with FDS for Pemvidutide in the Treatment of Obesity

Altimmune, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Regulatory And Clinical Catalysts Ahead For Altimmune

Consider Buying Potential Takeover Target Altimmune

Altimmune, Inc. Completes Enrollment in Phase 2B Impact Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (Mash)

Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Altimmune: Emerging Position In Competitive Space, But Risks Remain

Altimmune, Inc., Annual General Meeting, Sep 26, 2024

Altimmune, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Altimmune, Inc. Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology

Altimmune, Inc. Announces Demise of Richard Eisenstadt, Chief Financial Officer

Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note

Altimmune, Inc. Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity at the American Diabetes Association’s 84th Scientific Sessions

Altimmune, Inc. Presents Data at EASL International Liver Congress™? 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.40 loss in 1Q 2023)

Pomerantz LLP Announces Filing of Class Action Against Altimmune, Inc. and Certain Officers

Altimmune, Inc. to Report Q1, 2024 Results on May 09, 2024

Buy Altimmune's Potential Market Disruption With Pemvidutide

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place

Altimmune, Inc. Announces Impairment Loss for the Three Months Ended December 31, 2023

Altimmune, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally

Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

President exercised options and sold US$115k worth of stock